BRCA1 and ovarian carcinoma: The National Comprehensive Cancer Network (NCCN) guidelines currently recommend testing for germline and somatic BRCA1/2, other HR pathway genes, and microsatellite instability or DNA mismatch repair, which would fail to identify tumors with CCNE1 alterations (NCCN Guidelines Version 1.2022—Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer).